UroGen Pharma (FRA:UR8) Construction In Progress: €0.0 Mil (As of Mar. 2026)


FRA:UR8 UroGen Pharma Ltd FRA:UR8
61 GF Score
Price €33.40
GF Value €17.83
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Construction In Progress?

UroGen Pharma FRA:UR8 +7.85% 61 Construction In Progress is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 61/100 and a GF Value™ of €17.83 (Significantly Overvalued). The stock has 10 warning signs investors should review.

UroGen Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Construction In Progress Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:UR8
61GF Score
UroGen Pharma Ltd FRA:UR8
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.0 Mil mean?
UroGen Pharma (FRA:UR8) has a Construction In Progress of €0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's Construction In Progress too high?
UroGen Pharma's current Construction In Progress is €0.0 Mil. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Construction In Progress compare to SEPN and FTRE?
UroGen Pharma's Construction In Progress of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Construction In Progress is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.83, compared to a current price of €33.40 — trading 87.3% above its estimated fair value. The current Construction In Progress is €0.0 Mil. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Construction In Progress is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €33.40 is trading 87.3% above its estimated GF Value™ of €17.83. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Construction In Progress: €0.0 Mil
  • GF Value™: €17.83 vs. price of €33.40 (87.3% above fair value)
  • GF Score™: 61/100 with 10 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score

Get the complete analysis for FRA:UR8

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.40
Price
€17.83
GF Value